卡瑞利珠单抗和信迪利单抗治疗晚期食管癌患者的安全性及对预后的影响OA

Objective To compare the safety of Camrelizumab and Sintilimab on patients with advanced esophageal cancer,and to analyze their prognostic outcomes.Methods A retrospective analysis was conducted on 156 patients with advanced esophageal cancer admitted to our hospital from January 2021 to June 2025.According to the treatment methods received by the patients,they were divided into the Camrelizumab group(n=72)and the Sintilimab group(n=84).The tumor characteristics and occurrence of adverse reactions between the two groups were compared,and the prognosis of the two groups was analyzed.Results There was no significant difference in the levels of carcinoembryonic antigen,tumor location,TNM stage,tumor type,and differentiation grade between the two groups upon admission(P＞0.05).Compared with the Sintilimab group[21.43％(18/84)],the incidence of reactive capillary hyperplasia was significantly increased in the Camrelizumab group[73.61％(53/72)].Kaplan-Meier survival function analysis showed that compared with the Camrelizumab group,the progression-free survival(PFS)of patients in the Sintilimab group was significantly prolonged(P＜0.05);there was no significant difference in overall survival between the two groups(P＞0.05).Sintilimab significantly prolonged the PFS of patients with TNM stage Ⅳ disease(P＜0.05).Conclusion Camrelizumab and Sintilimab have comparable adverse reaction rates in patients with advanced esophageal cancer,but Sintilimab significantly prolongs PFS.